Frontiers in Psychiatry · Nov 17, 2026

Anticholinergic and benzodiazepine use in dementia: a systematic review with meta-analysis of anticholinergic burden and all-cause mortality

By Himika TN, Jarl J, Gerdtham UG et al.

Background: Dementia affects an estimated 57 million people worldwide, and this number is expected to rise sharply. People living with dementia (PwD) are especially vulnerable to medication-related harm due to frailty, multimorbidity, and polypharmacy. Two important forms of potentially inappropriate prescribing (PIP) that risk more harm than benefit in PwD are anticholinergic medicines (ACMs) and benzodiazepines (BZDs). This systematic review and meta-analysis examined the relationship between ACM and BZD use and adverse clinical outcomes in PwD. Methods: This systematic review followed PRISMA guidelines and was registered in PROSPERO. PubMed/MEDLINE, Embase, Web of Science, and CINAHL were searched for studies published between 1 January 2000 and 31 January 2026. Eligible studies included people with a diagnosis of dementia exposed to ACMs or BZDs, with a comparator group of no or lower exposure, and reporting at least one clinically relevant outcome. Randomized trials and observational studies were included. Risk of bias was assessed using RoB 2 for randomized trials and the Newcastle–Ottawa Scale for observational studies. GRADE was applied to meta-analyzed evidence. Where studies were sufficiently comparable in terms of exposure definition and outcome, effect estimates were pooled using a random-effects model with restricted maximum likelihood estimation. Quantitative synthesis was conducted for anticholinergic burden and all-cause mortality; remaining outcomes were synthesized narratively. Results: Thirty-eight studies were included: 20 on ACMs, 11 on BZDs, and 7 on combined exposure. Mortality was the most consistently reported clinical outcome. Meta-analysis was feasible for anticholinergic burden and all-cause mortality only (four studies; n = 86,056), showing a pooled HR of 1.16 (95% CI 1.07–1.26). Findings for delirium, hospitalization, cognitive decline, and functional decline were heterogeneous, although generally suggestive of potential harm. The certainty of evidence for the pooled mortality estimate was very low (GRADE). Conclusion: The available evidence suggests that ACM and BZD use in PwD is associated with a range of adverse clinical outcomes, with the most consistent evidence observed for mortality. However, the certainty of the pooled mortality estimate is very low, limiting causal interpretation and confidence in the magnitude of the association. These findings are consistent with current recommendations for cautious, individualized prescribing, regular medication review, and deprescribing where clinically appropriate. Future research should use more standardized exposure definitions, stronger causal-inference designs, and clinically relevant patient-centered outcomes to clarify whether reducing ACM and BZD exposure improves health and quality of life in PwD.

doi.org/10.3389/fpsyt.2026.1935225Open accessInterventions

AgingResearch.News